Ulodesine succinate anhydrous - CAS 1246200-39-4

Ulodesine (also known as BCX4208) is a purine nucleotide phosphorylase (PNP) inhibitor being developed by Biocryst for the treatment of gout. Intended as a once-daily oral therapy, it functions by impacting the purine metabolic pathway upstream of xanthine oxidase to decrease serum uric acid (sUA) levels. Its half-maximal inhibitory concentration (IC (50) ) for PNP is 0.5 nM. Currently, BCX-4208 is in early clinical trials to evaluate its potential benefits in treating psoriasis and gout.

1246157

C12H16N4O3 1/2C4H6O4

323.325

OC(CCC(O)=O)=O.O=C(N=CN1)C2=C1C(CN3C[C@@H]([C@H](C3)O)CO)=CN2.O=C(N=CN4)C5=C4C(CN6C[C@@H]([C@H](C6)O)CO)=CN5

-20°C

Ice Packs

Small Compound